{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T07:20:37Z","timestamp":1782458437403,"version":"3.54.5"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,14]]},"DOI":"10.7759\/cureus.36140","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T15:56:07Z","timestamp":1678809367000},"source":"Crossref","is-referenced-by-count":6,"title":["Hemophagocytic Syndrome and COVID-19: A Comprehensive Review"],"prefix":"10.7759","author":[{"given":"Mahdi M","family":"Fadlallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam M","family":"Fadlallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Rahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum DC","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020, 383:2255-73. 10.1056\/NEJMra2026131","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/15353702211068840","article-title":"Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?","volume":"247","author":"Liu JM","year":"2022","unstructured":"Liu JM, Chi J. Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?. Exp Biol Med (Maywood). 2022, 247:330-7. 10.1177\/15353702211068840","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2014.03.002","article-title":"Hemophagocytic syndromes \u2014 an update","volume":"28","author":"Janka GE","year":"2014","unstructured":"Janka GE, Lehmberg K. Hemophagocytic syndromes \u2014 an update. Blood Rev. 2014, 28:135-42. 10.1016\/j.blre.2014.03.002","journal-title":"Blood Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05569-4","article-title":"Haemophagocytic syndrome and COVID-19","volume":"40","author":"Retamozo S","year":"2021","unstructured":"Retamozo S, Brito-Zer\u00f3n P, Sis\u00f3-Almirall A, Flores-Ch\u00e1vez A, Soto-C\u00e1rdenas MJ, Ramos-Casals M. Haemophagocytic syndrome and COVID-19. Clin Rheumatol. 2021, 40:1233-44. 10.1007\/s10067-020-05569-4","journal-title":"Clin Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5045\/br.2021.2020323","article-title":"Current status of the diagnosis and treatment of hemophagocytic lymphohistiocytosis in adults","volume":"56","author":"Kim YR","year":"2021","unstructured":"Kim YR, Kim DY. Current status of the diagnosis and treatment of hemophagocytic lymphohistiocytosis in adults. Blood Res. 2021, 56:S17-25. 10.5045\/br.2021.2020323","journal-title":"Blood Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04636-y","article-title":"Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic","volume":"41","author":"Soy M","year":"2021","unstructured":"Soy M, Atag\u00fcnd\u00fcz P, Atag\u00fcnd\u00fcz I, Sucak GT. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatol Int. 2021, 41:7-18. 10.1007\/s00296-020-04636-y","journal-title":"Rheumatol Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of the 'cytokine storm' in COVID-19","volume":"80","author":"Ye Q","year":"2020","unstructured":"Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'cytokine storm' in COVID-19. J Infect. 2020, 80:607-13. 10.1016\/j.jinf.2020.03.037","journal-title":"J Infect"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.54729\/IEFL7714","article-title":"COVID-19 in Lebanon: demographics and distribution","volume":"4","author":"Fadlallah M","year":"2022","unstructured":"Fadlallah M, Hobeiche F, Jamal MT, Salem-Sokhn E. COVID-19 in Lebanon: demographics and distribution. BAU J Health Wellbeing. 2022, 4:7. 10.54729\/IEFL7714","journal-title":"BAU J Health Wellbeing"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0802-RA","article-title":"Hemophagocytic lymphohistiocytosis","volume":"146","author":"Ponnatt TS","year":"2022","unstructured":"Ponnatt TS, Lilley CM, Mirza KM. Hemophagocytic lymphohistiocytosis. Arch Pathol Lab Med. 2022, 146:507-19. 10.5858\/arpa.2020-0802-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.14829","article-title":"A case of hemophagocytic lymphohistiocytosis induced by COVID-19, and review of all cases reported in the literature","volume":"15","author":"Kayaaslan BU","year":"2021","unstructured":"Kayaaslan BU, Asilturk D, Eser F, Korkmaz M, Kucuksahin O, Pamukcuoglu M, Guner R. A case of hemophagocytic lymphohistiocytosis induced by COVID-19, and review of all cases reported in the literature. J Infect Dev Ctries. 2021, 15:1607-14. 10.3855\/jidc.14829","journal-title":"J Infect Dev Ctries"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01682-y","article-title":"Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?","volume":"18","author":"Opoka-Winiarska V","year":"2020","unstructured":"Opoka-Winiarska V, Grywalska E, Roli\u0144ski J. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?. BMC Med. 2020, 18:214. 10.1186\/s12916-020-01682-y","journal-title":"BMC Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107386","article-title":"Genetic features of late onset primary hemophagocytic lymphohistiocytosis in adolescence or adulthood","volume":"9","author":"Wang Y","year":"2014","unstructured":"Wang Y, Wang Z, Zhang J, et al.. Genetic features of late onset primary hemophagocytic lymphohistiocytosis in adolescence or adulthood. PLoS One. 2014, 9:e107386. 10.1371\/journal.pone.0107386","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP4ZDKJ4ICOUAT","article-title":"Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis","volume":"139","author":"Rosado FG","year":"2013","unstructured":"Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013, 139:713-27. 10.1309\/AJCP4ZDKJ4ICOUAT","journal-title":"Am J Clin Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.605","article-title":"Hemophagocytic lymphohistiocytosis: pathogenesis and treatment","volume":"2013","author":"Janka GE","year":"2013","unstructured":"Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program. 2013, 2013:605-11. 10.1182\/asheducation-2013.1.605","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref15","article-title":"Familial hemophagocytic lymphohistiocytosis","author":"Zhang K","year":"2023","unstructured":"Zhang K, Astigarraga I, Bryceson Y, et al.. Familial hemophagocytic lymphohistiocytosis. GeneReviews\u00ae. Adam MP, Mirzaa GM, Pagon RA, et al. (ed): University of Washington, Seattle, WA; 2023."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2015.06.007","article-title":"Pathogenesis of hemophagocytic lymphohistiocytosis","volume":"29","author":"Filipovich AH","year":"2015","unstructured":"Filipovich AH, Chandrakasan S. Pathogenesis of hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 2015, 29:895-902. 10.1016\/j.hoc.2015.06.007","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3109\/03009734.2015.1064500","article-title":"Secondary haemophagocytic lymphohistiocytosis: experience from the Uppsala University Hospital","volume":"120","author":"Karlsson T","year":"2015","unstructured":"Karlsson T. Secondary haemophagocytic lymphohistiocytosis: experience from the Uppsala University Hospital. Ups J Med Sci. 2015, 120:257-62. 10.3109\/03009734.2015.1064500","journal-title":"Ups J Med Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)61048-x","article-title":"Adult haemophagocytic syndrome","volume":"383","author":"Ramos-Casals M","year":"2014","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014, 383:1503-16. 10.1016\/s0140-6736(13)61048-x","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4328","article-title":"Hemophagocytic lymphohistiocytosis associated with HBV-HCV coinfection in adult: case report","volume":"9","author":"Bendari M","year":"2021","unstructured":"Bendari M, Delsa H, Bouanani N, et al.. Hemophagocytic lymphohistiocytosis associated with HBV-HCV coinfection in adult: case report. Clin Case Rep. 2021, 9:e04328. 10.1002\/ccr3.4328","journal-title":"Clin Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01102","article-title":"How viruses contribute to the pathogenesis of hemophagocytic lymphohistiocytosis","volume":"8","author":"Brisse E","year":"2017","unstructured":"Brisse E, Wouters CH, Andrei G, Matthys P. How viruses contribute to the pathogenesis of hemophagocytic lymphohistiocytosis. Front Immunol. 2017, 8:1102. 10.3389\/fimmu.2017.01102","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens EM","year":"2011","unstructured":"Behrens EM, Canna SW, Slade K, et al.. Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011, 121:2264-77. 10.1172\/JCI43157","journal-title":"J Clin Invest"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.6.1882","article-title":"Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection","volume":"98","author":"Kasahara Y","year":"2001","unstructured":"Kasahara Y, Yachie A, Takei K, et al.. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood. 2001, 98:1882-8. 10.1182\/blood.v98.6.1882","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140964","article-title":"Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time","volume":"212","author":"Jenkins MR","year":"2015","unstructured":"Jenkins MR, Rudd-Schmidt JA, Lopez JA, et al.. Failed CTL\/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time. J Exp Med. 2015, 212:307-17. 10.1084\/jem.20140964","journal-title":"J Exp Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1406","article-title":"Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome","volume":"106","author":"Chuang HC","year":"2005","unstructured":"Chuang HC, Lay JD, Hsieh WC, Wang HC, Chang Y, Chuang SE, Su IJ. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood. 2005, 106:3090-6. 10.1182\/blood-2005-04-1406","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001187","article-title":"Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP","volume":"9","author":"Palendira U","year":"2011","unstructured":"Palendira U, Low C, Chan A, et al.. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol. 2011, 9:e1001187. 10.1371\/journal.pbio.1001187","journal-title":"PLoS Biol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.8.4530","article-title":"Insufficient perforin expression in CD8+ T cells in response to hemagglutinin from avian influenza (H5N1) virus","volume":"176","author":"Hsieh SM","year":"2006","unstructured":"Hsieh SM, Chang SC. Insufficient perforin expression in CD8+ T cells in response to hemagglutinin from avian influenza (H5N1) virus. J Immunol. 2006, 176:4530-3. 10.4049\/jimmunol.176.8.4530","journal-title":"J Immunol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006097","article-title":"NK cells: energized yet exhausted in adult HLH","volume":"136","author":"Nichols KE","year":"2020","unstructured":"Nichols KE, Hines MR. NK cells: energized yet exhausted in adult HLH. Blood. 2020, 136:524-5. 10.1182\/blood.2020006097","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-370148","article-title":"Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH","volume":"118","author":"Zhang K","year":"2011","unstructured":"Zhang K, Jordan MB, Marsh RA, et al.. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011, 118:5794-8. 10.1182\/blood-2011-07-370148","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19230","article-title":"A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions","volume":"8","author":"Wang H","year":"2017","unstructured":"Wang H, Xiong L, Tang W, Zhou Y, Li F. A systematic review of malignancy-associated hemophagocytic lymphohistiocytosis that needs more attentions. Oncotarget. 2017, 8:59977-85. 10.18632\/oncotarget.19230","journal-title":"Oncotarget"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.551153","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center","volume":"52","author":"Machaczka M","year":"2011","unstructured":"Machaczka M, Vaktn\u00e4s J, Klimkowska M, H\u00e4gglund H. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. Leuk Lymphoma. 2011, 52:613-9. 10.3109\/10428194.2010.551153","journal-title":"Leuk Lymphoma"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30826","article-title":"A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults","volume":"123","author":"Daver N","year":"2017","unstructured":"Daver N, McClain K, Allen CE, et al.. A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. Cancer. 2017, 123:3229-40. 10.1002\/cncr.30826","journal-title":"Cancer"},{"key":"ref32","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: a multicenter study from Turkey","volume":"51","author":"Celkan T","year":"2009","unstructured":"Celkan T, Berrak S, Kazanci E, et al.. Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: a multicenter study from Turkey. Turk J Pediatr. 2009, 51:207-13.","journal-title":"Turk J Pediatr"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1159\/000312628","article-title":"Macrophage activation syndrome in autoimmune disease","volume":"153","author":"Deane S","year":"2010","unstructured":"Deane S, Selmi C, Teuber SS, Gershwin ME. Macrophage activation syndrome in autoimmune disease. Int Arch Allergy Immunol. 2010, 153:109-20. 10.1159\/000312628","journal-title":"Int Arch Allergy Immunol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/art.11368","article-title":"Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review","volume":"49","author":"Dhote R","year":"2003","unstructured":"Dhote R, Simon J, Papo T, et al.. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003, 49:633-9. 10.1002\/art.11368","journal-title":"Arthritis Rheum"},{"key":"ref35","article-title":"Pancytopenia secondary to hemophagocytic syndrome in rheumatoid arthritis treated with methotrexate and sulfasalazine","volume":"25","author":"Sibilia J","year":"1998","unstructured":"Sibilia J, Javier RM, Albert A, Cazenave JP, Kuntz JL. Pancytopenia secondary to hemophagocytic syndrome in rheumatoid arthritis treated with methotrexate and sulfasalazine. J Rheumatol. 1998, 25:1218-20.","journal-title":"J Rheumatol"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1097\/00005792-198811000-00002","article-title":"Hematophagic histiocytosis. A report of 23 new patients and a review of the literature","volume":"67","author":"Reiner AP","year":"1988","unstructured":"Reiner AP, Spivak JL. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore). 1988, 67:369-88.","journal-title":"Medicine (Baltimore)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.624687","article-title":"NK cells in autoimmune diseases: protective or pathogenic?","volume":"12","author":"Liu M","year":"2021","unstructured":"Liu M, Liang S, Zhang C. NK cells in autoimmune diseases: protective or pathogenic?. Front Immunol. 2021, 12:624687. 10.3389\/fimmu.2021.624687","journal-title":"Front Immunol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter JI","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, et al.. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007, 48:124-31. 10.1002\/pbc.21039","journal-title":"Pediatr Blood Cancer"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet L","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, et al.. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014, 66:2613-20. 10.1002\/art.38690","journal-title":"Arthritis Rheumatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw076","article-title":"Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients","volume":"145","author":"Debaugnies F","year":"2016","unstructured":"Debaugnies F, Mahadeb B, Ferster A, Meuleman N, Rozen L, Demulder A, Corazza F. Performances of the H-score for diagnosis of hemophagocytic lymphohistiocytosis in adult and pediatric patients. Am J Clin Pathol. 2016, 145:862-70. 10.1093\/ajcp\/aqw076","journal-title":"Am J Clin Pathol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan MB","year":"2011","unstructured":"Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011, 118:4041-52. 10.1182\/blood-2011-03-278127","journal-title":"Blood"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1177\/1535370220962043","article-title":"Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients","volume":"246","author":"Hakim NN","year":"2021","unstructured":"Hakim NN, Chi J, Olazagasti C, Liu JM. Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients. Exp Biol Med (Maywood). 2021, 246:5-9. 10.1177\/1535370220962043","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01708","article-title":"Cytokine storm in COVID-19: the current evidence and treatment strategies","volume":"11","author":"Tang Y","year":"2020","unstructured":"Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020, 11:1708. 10.3389\/fimmu.2020.01708","journal-title":"Front Immunol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang C","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501120-20200224-00088","article-title":"Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019. (Article in Chinese)","volume":"36","author":"Chen C","year":"2020","unstructured":"Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019. (Article in Chinese). Zhonghua Shao Shang Za Zhi. 2020, 36:471-5. 10.3760\/cma.j.cn501120-20200224-00088","journal-title":"Zhonghua Shao Shang Za Zhi"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27405","article-title":"Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19","volume":"94","author":"Manik M","year":"2022","unstructured":"Manik M, Singh RK. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. J Med Virol. 2022, 94:869-77. 10.1002\/jmv.27405","journal-title":"J Med Virol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848582","article-title":"Adaptive immune responses and immunity to SARS-CoV-2","volume":"13","author":"Primorac D","year":"2022","unstructured":"Primorac D, Vrdoljak K, Brlek P, et al.. Adaptive immune responses and immunity to SARS-CoV-2. Front Immunol. 2022, 13:848582. 10.3389\/fimmu.2022.848582","journal-title":"Front Immunol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.921452","article-title":"Immunomodulatory therapies for COVID-19","volume":"9","author":"Mathur P","year":"2022","unstructured":"Mathur P, Kottilil S. Immunomodulatory therapies for COVID-19. Front Med (Lausanne). 2022, 9:921452. 10.3389\/fmed.2022.921452","journal-title":"Front Med (Lausanne)"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.4110\/in.2018.18.e27","article-title":"Damage-associated molecular patterns in inflammatory diseases","volume":"18","author":"Roh JS","year":"2018","unstructured":"Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw. 2018, 18:e27. 10.4110\/in.2018.18.e27","journal-title":"Immune Netw"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.09.004","article-title":"Exhausted NK cells and cytokine storms in COVID-19: whether NK cell therapy could be a therapeutic choice","volume":"83","author":"Ghasemzadeh M","year":"2022","unstructured":"Ghasemzadeh M, Ghasemzadeh A, Hosseini E. Exhausted NK cells and cytokine storms in COVID-19: whether NK cell therapy could be a therapeutic choice. Hum Immunol. 2022, 83:86-98. 10.1016\/j.humimm.2021.09.004","journal-title":"Hum Immunol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00825-2","article-title":"NK cell dysfunction in patients with COVID-19","volume":"19","author":"Bi J","year":"2022","unstructured":"Bi J. NK cell dysfunction in patients with COVID-19. Cell Mol Immunol. 2022, 19:127-9. 10.1038\/s41423-021-00825-2","journal-title":"Cell Mol Immunol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002650","article-title":"Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19","volume":"4","author":"Osman M","year":"2020","unstructured":"Osman M, Faridi RM, Sligl W, et al.. Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. Blood Adv. 2020, 4:5035-9. 10.1182\/bloodadvances.2020002650","journal-title":"Blood Adv"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/art.39295","article-title":"Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome","volume":"67","author":"Cifaldi L","year":"2015","unstructured":"Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Locatelli F, De Benedetti F, Strippoli R. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015, 67:3037-46. 10.1002\/art.39295","journal-title":"Arthritis Rheumatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138554","article-title":"Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent","volume":"130","author":"Mazzoni A","year":"2020","unstructured":"Mazzoni A, Salvati L, Maggi L, et al.. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020, 130:4694-703. 10.1172\/JCI138554","journal-title":"J Clin Invest"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng M","year":"2020","unstructured":"Zheng M, Gao Y, Wang G, et al.. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020, 17:533-5. 10.1038\/s41423-020-0402-2","journal-title":"Cell Mol Immunol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0944-y","article-title":"A single-cell atlas of the peripheral immune response in patients with severe COVID-19","volume":"26","author":"Wilk AJ","year":"2020","unstructured":"Wilk AJ, Rustagi A, Zhao NQ, et al.. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020, 26:1070-6. 10.1038\/s41591-020-0944-y","journal-title":"Nat Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.06.001","article-title":"The 'cytokine storm': molecular mechanisms and therapeutic prospects","volume":"42","author":"Karki R","year":"2021","unstructured":"Karki R, Kanneganti TD. The 'cytokine storm': molecular mechanisms and therapeutic prospects. Trends Immunol. 2021, 42:681-705. 10.1016\/j.it.2021.06.001","journal-title":"Trends Immunol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2014 final report","volume":"383","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al.. Remdesivir for the treatment of Covid-19 \u2014 final report. N Engl J Med. 2020, 383:1813-26. 10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01500-9","article-title":"Calming the cytokine storm in COVID-19","volume":"27","author":"Cron RQ","year":"2021","unstructured":"Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-19. Nat Med. 2021, 27:1674-5. 10.1038\/s41591-021-01500-9","journal-title":"Nat Med"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3906\/biy-2105-37","article-title":"Pathogenesis and treatment of cytokine storm in COVID-19","volume":"45","author":"Soy M","year":"2021","unstructured":"Soy M, Keser G, Atag\u00fcnd\u00fcz P. Pathogenesis and treatment of cytokine storm in COVID-19. Turk J Biol. 2021, 45:372-89. 10.3906\/biy-2105-37","journal-title":"Turk J Biol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby P","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021, 384:693-704. 10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo P","year":"2020","unstructured":"Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020, 92:814-8. 10.1002\/jmv.25801","journal-title":"J Med Virol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25897","article-title":"Off-label use of tocilizumab in patients with SARS-CoV-2 infection","volume":"92","author":"Di Giambenedetto S","year":"2020","unstructured":"Di Giambenedetto S, Ciccullo A, Borghetti A, et al.. Off-label use of tocilizumab in patients with SARS-CoV-2 infection. J Med Virol. 2020, 92:1787-8. 10.1002\/jmv.25897","journal-title":"J Med Virol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu X","year":"2020","unstructured":"Xu X, Han M, Li T, et al.. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020, 117:10970-5. 10.1073\/pnas.2005615117","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6615","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani C","year":"2021","unstructured":"Salvarani C, Dolci G, Massari M, et al.. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021, 181:24-31. 10.1001\/jamainternmed.2020.6615","journal-title":"JAMA Intern Med"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","author":"Gordon AC","year":"2021","unstructured":"Gordon AC, Mouncey PR, Al-Beidh F, et al.. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021, 384:1491-502. 10.1056\/NEJMoa2100433","journal-title":"N Engl J Med"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama C","year":"2021","unstructured":"Salama C, Han J, Yau L, et al.. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021, 384:20-30. 10.1056\/NEJMoa2030340","journal-title":"N Engl J Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine O","year":"2021","unstructured":"Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021, 181:32-40. 10.1001\/jamainternmed.2020.6820","journal-title":"JAMA Intern Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021, 397:1637-45. 10.1016\/S0140-6736(21)00676-0","journal-title":"Lancet"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109906","article-title":"Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: targeting a potential IL-1\u03b2\/neutrophil extracellular traps feedback loop","volume":"143","author":"Yaqinuddin A","year":"2020","unstructured":"Yaqinuddin A, Kashir J. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: targeting a potential IL-1\u03b2\/neutrophil extracellular traps feedback loop. Med Hypotheses. 2020, 143:109906. 10.1016\/j.mehy.2020.109906","journal-title":"Med Hypotheses"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","volume":"2","author":"Huet T","year":"2020","unstructured":"Huet T, Beaussier H, Voisin O, et al.. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020, 2:e393-400. 10.1016\/S2665-9913(20)30164-8","journal-title":"Lancet Rheumatol"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001126","article-title":"IL-1 receptor antagonist anakinra in the treatment of COVID-19 acute respiratory distress syndrome: a retrospective, observational study","volume":"206","author":"Franzetti M","year":"2021","unstructured":"Franzetti M, Forastieri A, Borsa N, et al.. IL-1 receptor antagonist anakinra in the treatment of COVID-19 acute respiratory distress syndrome: a retrospective, observational study. J Immunol. 2021, 206:1569-75. 10.4049\/jimmunol.2001126","journal-title":"J Immunol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial","volume":"9","author":"CORIMUNO-19 Collaborative Group","year":"2021","unstructured":"CORIMUNO-19 Collaborative Group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021, 9:295-304. 10.1016\/S2213-2600(20)30556-7","journal-title":"Lancet Respir Med"},{"key":"ref74","article-title":"Features, Evaluation, and Treatment of Coronavirus (COVID-19)","author":"Cascella M","year":"2022","unstructured":"Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.06.007","article-title":"Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19","volume":"41","author":"Luo W","year":"2020","unstructured":"Luo W, Li YX, Jiang LJ, Chen Q, Wang T, Ye DW. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci. 2020, 41:531-43. 10.1016\/j.tips.2020.06.007","journal-title":"Trends Pharmacol Sci"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with COVID-19","volume":"384","author":"Kalil AC","year":"2021","unstructured":"Kalil AC, Patterson TF, Mehta AK, et al.. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2021, 384:795-807. 10.1056\/NEJMoa2031994","journal-title":"N Engl J Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi VC","year":"2021","unstructured":"Marconi VC, Ramanan AV, de Bono S, et al.. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021, 9:1407-18. 10.1016\/S2213-2600(21)00331-3","journal-title":"Lancet Respir Med"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101489","article-title":"Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials","volume":"49","author":"Selvaraj V","year":"2022","unstructured":"Selvaraj V, Finn A, Lal A, Khan MS, Dapaah-Afriyie K, Carino GP. Baricitinib in hospitalised patients with COVID-19: a meta-analysis of randomised controlled trials. EClinicalMedicine. 2022, 49:101489. 10.1016\/j.eclinm.2022.101489","journal-title":"EClinicalMedicine"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00539-7","article-title":"Stimulating severe COVID-19: the potential role of GM-CSF antagonism","volume":"10","author":"Leavis HL","year":"2022","unstructured":"Leavis HL, van de Veerdonk FL, Murthy S. Stimulating severe COVID-19: the potential role of GM-CSF antagonism. Lancet Respir Med. 2022, 10:223-4. 10.1016\/S2213-2600(21)00539-7","journal-title":"Lancet Respir Med"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00494-X","article-title":"Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial","volume":"10","author":"Temesgen Z","year":"2022","unstructured":"Temesgen Z, Burger CD, Baker J, et al.. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2022, 10:237-46. 10.1016\/S2213-2600(21)00494-X","journal-title":"Lancet Respir Med"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01870-2021","article-title":"A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)","volume":"61","author":"Patel J","year":"2023","unstructured":"Patel J, Bass D, Beishuizen A, et al.. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR). Eur Respir J. 2023, 61:2101870. 10.1183\/13993003.01870-2021","journal-title":"Eur Respir J"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00070-9","article-title":"Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial","volume":"3","author":"Cremer PC","year":"2021","unstructured":"Cremer PC, Abbate A, Hudock K, et al.. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021, 3:e410-8. 10.1016\/S2665-9913(21)00070-9","journal-title":"Lancet Rheumatol"},{"key":"ref83","unstructured":"COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. (2022). https.\/\/www.covid19treatmentguidelines.nih.gov\/."},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062967","article-title":"Do COVID-19 infections result in a different form of secondary hemophagocytic lymphohistiocytosis","volume":"22","author":"Chu R","year":"2021","unstructured":"Chu R, van Eeden C, Suresh S, Sligl WI, Osman M, Cohen Tervaert JW. Do COVID-19 infections result in a different form of secondary hemophagocytic lymphohistiocytosis. Int J Mol Sci. 2021, 22:2967. 10.3390\/ijms22062967","journal-title":"Int J Mol Sci"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2021-0053","article-title":"Secondary haemophagocytic lymphohistiocytosis in hospitalised COVID-19 patients as indicated by a modified HScore is infrequent and high scores do not associate with increased mortality","volume":"21","author":"Ardern-Jones MR","year":"2021","unstructured":"Ardern-Jones MR, Stammers M, Phan HT, et al.. Secondary haemophagocytic lymphohistiocytosis in hospitalised COVID-19 patients as indicated by a modified HScore is infrequent and high scores do not associate with increased mortality. Clin Med (Lond). 2021, 21:e543-7. 10.7861\/clinmed.2021-0053","journal-title":"Clin Med (Lond)"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16735","article-title":"Incidence of secondary hemophagocytic lymphohistiocytosis in critically-ill COVID-19 patients","volume":"13","author":"Allen J","year":"2021","unstructured":"Allen J, McCambridge MM, Kincaid H, Kalter JA. Incidence of secondary hemophagocytic lymphohistiocytosis in critically-ill COVID-19 patients. Cureus. 2021, 13:e16735. 10.7759\/cureus.16735","journal-title":"Cureus"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06094-8","article-title":"Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients","volume":"21","author":"Meng M","year":"2021","unstructured":"Meng M, Chen L, Zhang S, et al.. Risk factors for secondary hemophagocytic lymphohistiocytosis in severe coronavirus disease 2019 adult patients. BMC Infect Dis. 2021, 21:398. 10.1186\/s12879-021-06094-8","journal-title":"BMC Infect Dis"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13310","article-title":"The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19","volume":"42","author":"Loscocco GG","year":"2020","unstructured":"Loscocco GG, Malandrino D, Barchiesi S, Berni A, Poggesi L, Guglielmelli P, Vannucchi AM. The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19. Int J Lab Hematol. 2020, 42:e270-3. 10.1111\/ijlh.13310","journal-title":"Int J Lab Hematol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218048","article-title":"Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences","volume":"79","author":"Ruscitti P","year":"2020","unstructured":"Ruscitti P, Bruno F, Berardicurti O, et al.. Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences. Ann Rheum Dis. 2020, 79:1152-5. 10.1136\/annrheumdis-2020-218048","journal-title":"Ann Rheum Dis"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16934","article-title":"Secondary HLH is uncommon in severe COVID-19","volume":"190","author":"Wood H","year":"2020","unstructured":"Wood H, Jones JR, Hui K, et al.. Secondary HLH is uncommon in severe COVID-19. Br J Haematol. 2020, 190:e283-5. 10.1111\/bjh.16934","journal-title":"Br J Haematol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-021-01706-0","article-title":"Assessment of the HScore as a predictor of disease outcome in patients with COVID-19","volume":"21","author":"Bordbar M","year":"2021","unstructured":"Bordbar M, Sanaei Dashti A, Amanati A, Shorafa E, Mansoori Y, Dehghani SJ, Molavi Vardanjani H. Assessment of the HScore as a predictor of disease outcome in patients with COVID-19. BMC Pulm Med. 2021, 21:338. 10.1186\/s12890-021-01706-0","journal-title":"BMC Pulm Med"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle D","year":"2020","unstructured":"McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020, 19:102537. 10.1016\/j.autrev.2020.102537","journal-title":"Autoimmun Rev"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1002\/art.41763","article-title":"Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkers","volume":"73","author":"Kessel C","year":"2021","unstructured":"Kessel C, Vollenberg R, Masjosthusmann K, et al.. Discrimination of COVID-19 from inflammation-induced cytokine storm syndromes using disease-related blood biomarkers. Arthritis Rheumatol. 2021, 73:1791-9. 10.1002\/art.41763","journal-title":"Arthritis Rheumatol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01626","article-title":"Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19","volume":"11","author":"Polidoro RB","year":"2020","unstructured":"Polidoro RB, Hagan RS, de Santis Santiago R, Schmidt NW. Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19. Front Immunol. 2020, 11:1626. 10.3389\/fimmu.2020.01626","journal-title":"Front Immunol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-207337","article-title":"Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore","volume":"75","author":"N\u00fa\u00f1ez-Torr\u00f3n C","year":"2022","unstructured":"N\u00fa\u00f1ez-Torr\u00f3n C, Ferrer-G\u00f3mez A, Moreno Moreno E, et al.. Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore. J Clin Pathol. 2022, 75:383-9. 10.1136\/jclinpath-2020-207337","journal-title":"J Clin Pathol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13619","article-title":"Hemophagocytic histiocytosis in severe SARS-CoV-2 infection: a bone marrow study","volume":"43","author":"Dandu H","year":"2021","unstructured":"Dandu H, Yadav G, Malhotra HS, Pandey S, Sachu R, Dubey K. Hemophagocytic histiocytosis in severe SARS-CoV-2 infection: a bone marrow study. Int J Lab Hematol. 2021, 43:1291-301. 10.1111\/ijlh.13619","journal-title":"Int J Lab Hematol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00793-y","article-title":"Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience","volume":"34","author":"Bryce C","year":"2021","unstructured":"Bryce C, Grimes Z, Pujadas E, et al.. Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Mod Pathol. 2021, 34:1456-67. 10.1038\/s41379-021-00793-y","journal-title":"Mod Pathol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i21.3394","article-title":"Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and \u03b3-immunoglobulin infusions","volume":"7","author":"Georgiadou S","year":"2019","unstructured":"Georgiadou S, Gatselis NK, Stefos A, Zachou K, Makaritsis K, Rigopoulou EI, Dalekos GN. Efficient management of secondary haemophagocytic lymphohistiocytosis with intravenous steroids and \u03b3-immunoglobulin infusions. World J Clin Cases. 2019, 7:3394-406. 10.12998\/wjcc.v7.i21.3394","journal-title":"World J Clin Cases"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19292","article-title":"Hemphagocytic lymphohistiocytosis secondary to COVID-19: a case report","volume":"13","author":"Naqvi WA","year":"2021","unstructured":"Naqvi WA, Bhutta MJ. Hemphagocytic lymphohistiocytosis secondary to COVID-19: a case report. Cureus. 2021, 13:e19292. 10.7759\/cureus.19292","journal-title":"Cureus"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17328","article-title":"Secondary hemophagocytic lymphohistiocytosis in post-COVID-19 patients: a report of two cases","volume":"13","author":"Kalita P","year":"2021","unstructured":"Kalita P, Laishram D, Dey B, Mishra J, Barman B, Barman H. Secondary hemophagocytic lymphohistiocytosis in post-COVID-19 patients: a report of two cases. Cureus. 2021, 13:e17328. 10.7759\/cureus.17328","journal-title":"Cureus"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22620","article-title":"Secondary hemophagocytic lymphohistiocytosis in a post-COVID-19 patient","volume":"14","author":"Bandaru SS","year":"2022","unstructured":"Bandaru SS, Capace A, Busa V, Williams A. Secondary hemophagocytic lymphohistiocytosis in a post-COVID-19 patient. Cureus. 2022, 14:e22620. 10.7759\/cureus.22620","journal-title":"Cureus"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-245031","article-title":"Haemophagocytic lymphohistiocytosis in an adult with postacute COVID-19 syndrome","volume":"14","author":"Wiseman D","year":"2021","unstructured":"Wiseman D, Lin J, Routy JP, Samoukovic G. Haemophagocytic lymphohistiocytosis in an adult with postacute COVID-19 syndrome. BMJ Case Rep. 2021, 14:e245031. 10.1136\/bcr-2021-245031","journal-title":"BMJ Case Rep"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.022","article-title":"Abnormality in the NK-cell population is prolonged in severe COVID-19 patients","volume":"148","author":"Leem G","year":"2021","unstructured":"Leem G, Cheon S, Lee H, et al.. Abnormality in the NK-cell population is prolonged in severe COVID-19 patients. J Allergy Clin Immunol. 2021, 148:996-1006.e18. 10.1016\/j.jaci.2021.07.022","journal-title":"J Allergy Clin Immunol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009499","article-title":"T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis","volume":"137","author":"Chaturvedi V","year":"2021","unstructured":"Chaturvedi V, Marsh RA, Zoref-Lorenz A, et al.. T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood. 2021, 137:2337-46. 10.1182\/blood.2020009499","journal-title":"Blood"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.735125","article-title":"Persistent high percentage of HLA-DR+CD38high CD8+ T cells associated with immune disorder and disease severity of COVID-19","volume":"12","author":"Du J","year":"2021","unstructured":"Du J, Wei L, Li G, et al.. Persistent high percentage of HLA-DR+CD38high CD8+ T cells associated with immune disorder and disease severity of COVID-19. Front Immunol. 2021, 12:735125. 10.3389\/fimmu.2021.735125","journal-title":"Front Immunol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102561","article-title":"Fatal COVID-19 infections: is NK cell dysfunction a link with autoimmune HLH?","volume":"19","author":"Osman MS","year":"2020","unstructured":"Osman MS, van Eeden C, Cohen Tervaert JW. Fatal COVID-19 infections: is NK cell dysfunction a link with autoimmune HLH?. Autoimmun Rev. 2020, 19:102561. 10.1016\/j.autrev.2020.102561","journal-title":"Autoimmun Rev"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-01322-6_9","article-title":"Diagnosis, treatment, and management of hemophagocytic lymphohistiocytosis in the critical care unit","author":"Hines M","year":"2019","unstructured":"Hines M, Bhatt N, Talano JA. Diagnosis, treatment, and management of hemophagocytic lymphohistiocytosis in the critical care unit. Critical Care of the Pediatric Immunocompromised Hematology\/Oncology Patient. Duncan C, Talano JA, McArthur J (ed): Springer, Cham, Switzerland; 2019. 10.1007\/978-3-030-01322-6_9"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26826","article-title":"Role of toll-like receptors in the pathogenesis of COVID-19","volume":"93","author":"Khanmohammadi S","year":"2021","unstructured":"Khanmohammadi S, Rezaei N. Role of toll-like receptors in the pathogenesis of COVID-19. J Med Virol. 2021, 93:2735-9. 10.1002\/jmv.26826","journal-title":"J Med Virol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.260307","article-title":"Perforin gene variant A91V in young patients with severe COVID-19","volume":"105","author":"Cabrera-Marante O","year":"2020","unstructured":"Cabrera-Marante O, Rodr\u00edguez de Fr\u00edas E, Pleguezuelo DE, et al.. Perforin gene variant A91V in young patients with severe COVID-19. Haematologica. 2020, 105:2844-6. 10.3324\/haematol.2020.260307","journal-title":"Haematologica"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-021-00886-x","article-title":"Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms","volume":"29","author":"Luo H","year":"2021","unstructured":"Luo H, Liu D, Liu W, et al.. Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms. Eur J Hum Genet. 2021, 29:1312-5. 10.1038\/s41431-021-00886-x","journal-title":"Eur J Hum Genet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/141278-hemophagocytic-syndrome-and-covid-19-a-comprehensive-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:08Z","timestamp":1707508508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/141278-hemophagocytic-syndrome-and-covid-19-a-comprehensive-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":110,"URL":"https:\/\/doi.org\/10.7759\/cureus.36140","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,14]]}}}